Evidence map›Paper›PMID 40903226›Full record

ArticleInternal medicine (Tokyo, Japan)2026

Male Sex, Diabetes Mellitus, and an Unvaccinated Status as Deteriorating Factors for Coronavirus Disease 2019 in Patients with Rheumatic Diseases: A Single-center Analysis in the North Kanto Region of Japan During the Omicron Variant Period.

Fuminori Taniguchi, Hironobu Komine, Kohei Morikawa, Haruka Kondo, Hiroi Kusaka, Shotaro Yamamoto, Jun Nakamura, Ayako Kokuzawa, Yasuyuki Kamata, Katsuya Nagatani and 2 more

Abstract read
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fuminori TaniguchiDivision of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Japan.
Hironobu KomineDivision of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Japan.
Kohei MorikawaDivision of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Japan.
Haruka KondoDivision of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Japan.
Hiroi KusakaDivision of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Japan.
Shotaro YamamotoDivision of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Japan.
Jun NakamuraDivision of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Japan.
Ayako KokuzawaDivision of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Japan.
Yasuyuki KamataDivision of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Japan.
Katsuya NagataniDivision of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Japan.
Takeo SatoDivision of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Japan.
Kojiro SatoDivision of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective This study aimed to analyze the risk factors for coronavirus disease 2019 (COVID-19) deterioration in patients with rheumatic disease. Methods We conducted a retrospective study of patients with rheumatic disease who were admitted to our division for COVID-19, as well as those who were confirmed to have developed COVID-19 at either an outpatient or in-hospital onset during the Omicron variant period between January 2022 and December 2023. We retrospectively collected data on the prefectures of residence, the underlying rheumatic diseases, medications, periods of COVID-19 diagnosis, total vaccination doses, severity, COVID-19 treatments, outcomes, and comorbidities from medical records. For inpatients, the blood test results at the time of diagnosis or admission were also collected. We conducted a multivariate logistic regression analysis to identify the deteriorating factors for COVID-19. Results We identified 78 patients from the North Kanto region of Japan who were diagnosed with COVID-19. Among them, 33 were hospitalized, two were diagnosed with COVID-19 in our outpatient division, and 43 were diagnosed at other hospitals. The disease was mild, moderate, severe, and critical in 61 (78.2%), five (6.4%), 10 (12.8%), and two (2.6%) patients, respectively. The significant risk factors for moderate-to-critical disease were a male sex (p=0.012), an unvaccinated status (p=0.031), and diabetes mellitus (p=0.018). No blood test results were significant according to the multivariate analysis. Conclusion Most patients with COVID-19 and rheumatic diseases had favorable outcomes during the Omicron period. The management of comorbidities, such as diabetes mellitus, and the facilitation of vaccination are important for preventing severe COVID-19.

Indexed as

COVID-19Diabetes MellitusRheumatic DiseasesAdultAgedAged, 80 and overCOVID-19 VaccinesFemaleHumansJapanMaleMiddle AgedRetrospective StudiesRisk FactorsSARS-CoV-2Severity of Illness IndexCOVID-19 VaccinesCOVID-19diabetes mellitusmultivariate logistic regression analysisOmicron variantrheumatic diseasesvaccination

Identifiers

PMID40903226
PMCPMC13175662

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.